Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7046 in advanced malignancies
NCT02540291Phase 1Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of palupiprant in pancreatic adenocarcinoma (PDAC), clear cell renal cell carcinoma (ccRCC), head and neck squamous cell carcinoma (HNSCC) and 7 more, sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events, Maximum Tolerated Dose and 1 more. Started Jul 2015; status: terminated.
02
Drugs
palupiprant
03
Conditions
pancreatic adenocarcinoma (PDAC)clear cell renal cell carcinoma (ccRCC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02540291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540291.